Verrucarin J

Verrucarin J (Muconomycin B) is a metabolite of the Myrothecium fungus family. Verrucarin J generates reactive oxygen species ( ROS ) and induces apoptosis of cancer cell lines, such as A549, HCT 116 and SW-620 cells. Verrucarin J shows activities against Candida albicans and Mucor miehei. Verrucarin J inhibits arenavirus Junin (JUNV) yield with an IC 50 of 1.2 ng/mL. In Vitro Verrucarin J (0, 5, 10, 20, 50 nM; 24 hours) induces the apoptosis of A549 cells. Verrucarin J (0, 1, 2, 5, 10, 20, 50 nM; 24, 48, 72 hours) significantly inhibits cell proliferation of A549 and H1793 cells with IC 50 values of approximately 10 nM and 20 nM after 48 h of treatment, respectively. Verrucarin J (0, 0.1, 0.2, 0.3, 0.4, 0.5 μM; 24 hours) has an IC 50 of 300 nM for HCT 116 and SW-620 cell proliferation. Verrucarin J (0, 10, 20 nM, 48 hours) inhibits cancer stem cell (CSC) self-renewal pathways Wnt1/β-catenin and Notch1 and down-regulates the expression of key CSC specific genes (ALDH1, LGR5, OCT4 and CD133) of A549 cells. Verrucarin J (compound 2; 50 μg/disk) shows noteworthy activities against Candida albicans and Mucor miehei. Verrucarin J reduces JUNV yield more than 2 log units and has a similar effect against the arenavirus Tacaribe . Verrucarin J reduces the cell viability of Vero cells with a cytotoxic concentration 50% (CC 50 ) of 8.2 ng/mL . MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Verrucarin J (0.5 mg/kg; i.p. for 4 weeks) suppresses AKT-induced tumor growth in a xenograft model. Verrucarin J (0.1, 0.5, 2.0 mg/kg; i.p. for three weeks) is a highly potent anticancer drug and suppresses tumor growth and metastasis. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-8 weeks old BALB/c athymic nude mice (nu/nu) with pCMV/HCT 116 and AKT/HCT 116 xenograftsDosage: 0.5 mg/kg body weight Administration: i.p. for 4 weeks Result: Reduced the expression of prosurvival markers pAKT, Notch1, p65, and Ki67 in all tumors. Animal Model: Female nude nu/nu (5 to 6 weeks old) mice with A2780 xenograftsDosage: 0.1, 0.5, 2.0 mg/kg (vehicle: 10% DMSO, 90% glyceryl trioctanoate) Administration: i.p. for three weeks after 10 days of injection of A2780 cells Result: Reduced tumor weight (32% lower compared to control), and reduced visible metastasis in 0.1 mg/kg. Showed a significant reduction in visible peritoneal tumors (61% lower compared to control group) and highly reduced visible metastasis in 0.5 mg/kg. Reduced ovarian tumor weight by 71% compared to vehicle in 0.5 mg/kg. In lethal dose 2 mg/kg, mice sick with a swollen belly, body fluid and subsequently died within 3 treatments. Form:Solid

No numbering system information yet

No physical and chemical property information yet

No safety information yet

No production method and use information yet

No upstream information yet

No downstream information yet

No related product information yet